Recombinant Human PD-L1/B7-H1 His-tag Protein, CF Summary
Phe19-Thr239, with a C-terminal 6-His tag
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Dong, H. et al. (2002) Nat. Med. 8:793.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
Citation for Recombinant Human PD-L1/B7-H1 His-tag Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Rapid PD-L1 detection in tumors with PET using a highly specific peptide
Authors: Samit Chatterjee
Biochem. Biophys. Res. Commun, 2016;0(0):.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Protein Purification Kits
Reviews for Recombinant Human PD-L1/B7-H1 His-tag Protein, CF
Average Rating: 5 (Based on 9 Reviews)
Have you used Recombinant Human PD-L1/B7-H1 His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image